
    
      The IMMUWIN phase II will test the safety and anti-tumor efficacy of the combination of
      durvalumab and tremelimumab with either TACE or Y-90 SIRT. Patients will be randomized into
      two experimental arms, one receiving SIRT + Durvalumab + Tremelimumab, the other arm
      receiving TACE + Durvalumab + Tremelimumab. It will be determined whether the combination of
      immunotherapy with SIRT or TACE is more promising.
    
  